

# Santosh Kesari

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8987222/publications.pdf>

Version: 2024-02-01

57  
papers

2,090  
citations

279798

23  
h-index

243625

44  
g-index

57  
all docs

57  
docs citations

57  
times ranked

3889  
citing authors

#	ARTICLE	IF	CITATIONS
1	&lt;p&gt;Lipid&dashpolymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, emerging technologies, and perspectives&lt;/p&gt;. International Journal of Nanomedicine, 2019, Volume 14, 1937-1952.	6.7	284
2	A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. Neuro-Oncology, 2016, 18, 1146-1156.	1.2	197
3	Phase I trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Science Translational Medicine, 2016, 8, 341ra75.	12.4	158
4	Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases. Cancer Cell International, 2014, 14, 26.	4.1	152
5	Brain metastases. Current Opinion in Neurology, 2005, 18, 654-661.	3.6	102
6	Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs. Journal of Translational Medicine, 2014, 12, 13.	4.4	87
7	A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer. Oncotarget, 2015, 6, 4527-4536.	1.8	85
8	Leptomeningeal metastasis in breast cancer - a systematic review. Oncotarget, 2016, 7, 3740-3747.	1.8	61
9	Effect of the JAK2/STAT3 inhibitor SAR317461 on human glioblastoma tumorspheres. Journal of Translational Medicine, 2015, 13, 269.	4.4	56
10	Plexin-B2 promotes invasive growth of malignant glioma. Oncotarget, 2015, 6, 7293-7304.	1.8	55
11	Protein interaction discovery using parallel analysis of translated ORFs (PLATO). Nature Biotechnology, 2013, 31, 331-334.	17.5	52
12	Targeting and depletion of circulating leukocytes and cancer cells by lipophilic antibody-modified erythrocytes. Journal of Controlled Release, 2014, 183, 146-153.	9.9	45
13	A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. Neuro-Oncology, 2016, 18, 849-854.	1.2	45
14	Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a <i>post hoc</i> analysis of the EF-14 trial. CNS Oncology, 2017, 6, 185-193.	3.0	43
15	Brainstem Glioma in Adults. Frontiers in Oncology, 2016, 6, 180.	2.8	42
16	Mitochondrial p32 is upregulated in Myc expressing brain cancers and mediates glutamine addiction. Oncotarget, 2015, 6, 1157-1170.	1.8	39
17	Antibody drug conjugates: Progress, pitfalls, and promises. Human Antibodies, 2018, 27, 53-62.	1.5	33
18	Further understanding of the pathology of glioma: implications for the clinic. Expert Review of Neurotherapeutics, 2016, 16, 1055-1065.	2.8	32

#	ARTICLE	IF	CITATIONS
19	Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine. <i>International Journal of Molecular Sciences</i> , 2017, 18, 995.	4.1	32
20	WNT Signaling as a Therapeutic Target for Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8428.	4.1	32
21	IGF2 mRNA binding protein 3 (IMP3) promotes glioma cell migration by enhancing the translation of RELA/p65. <i>Oncotarget</i> , 2017, 8, 40469-40485.	1.8	30
22	In silico modeling predicts drug sensitivity of patient-derived cancer cells. <i>Journal of Translational Medicine</i> , 2014, 12, 128.	4.4	26
23	A Novel Bioavailable BH3 Mimetic Efficiently Inhibits Colon Cancer via Cascade Effects of Mitochondria. <i>Clinical Cancer Research</i> , 2016, 22, 1445-1458.	7.0	25
24	High-Resolution Mutational Profiling Suggests the Genetic Validity of Glioblastoma Patient-Derived Pre-Clinical Models. <i>PLoS ONE</i> , 2013, 8, e56185.	2.5	25
25	Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies. <i>Oncotarget</i> , 2016, 7, 21556-21569.	1.8	24
26	A novel small molecule inhibitor of p32 mitochondrial protein overexpressed in glioma. <i>Journal of Translational Medicine</i> , 2017, 15, 210.	4.4	23
27	Multiple spatially related pharmacophores define small molecule inhibitors of OLIG2 in glioblastoma. <i>Oncotarget</i> , 2017, 8, 22370-22384.	1.8	23
28	Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study. <i>Journal of Neuro-Oncology</i> , 2014, 119, 361-368.	2.9	22
29	Anomaly Detection Framework for Wearables Data: A Perspective Review on Data Concepts, Data Analysis Algorithms and Prospects. <i>Sensors</i> , 2022, 22, 756.	3.8	22
30	Xenon in the treatment of panic disorder: an open label study. <i>Journal of Translational Medicine</i> , 2017, 15, 137.	4.4	21
31	Leptomeningeal Metastases. <i>Current Treatment Options in Oncology</i> , 2018, 19, 3.	3.0	20
32	The extrinsic coagulation cascade and tissue factor pathway inhibitor in macrophages: A potential therapeutic opportunity for atherosclerotic thrombosis. <i>Thrombosis Research</i> , 2014, 133, 657-666.	1.7	16
33	Pritumumab, the first therapeutic antibody for glioma patients. <i>Human Antibodies</i> , 2019, 26, 95-101.	1.5	16
34	Allosteric inhibitor of $\beta$ -catenin selectively targets oncogenic Wnt signaling in colon cancer. <i>Scientific Reports</i> , 2020, 10, 8096.	3.3	15
35	Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab142.	0.7	15
36	Cellular immunotherapy of cancer: an overview and future directions. <i>Immunotherapy</i> , 2017, 9, 589-606.	2.0	13

#	ARTICLE	IF	CITATIONS
37	IRE1 $\alpha$ and IGF signaling predict resistance to an endoplasmic reticulum stress-inducing drug in glioblastoma cells. <i>Scientific Reports</i> , 2020, 10, 8348.	3.3	13
38	Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia. <i>Science Translational Medicine</i> , 2022, 14, eabb7695.	12.4	13
39	Strategy and Technique of Endonasal Endoscopic Bony Decompression and Selective Tumor Removal in Symptomatic Skull Base Meningiomas of the Cavernous Sinus and Meckel's Cave. <i>World Neurosurgery</i> , 2019, 131, e12-e22.	1.3	12
40	Hyaluronan expression in primary and secondary brain tumors. <i>Annals of Translational Medicine</i> , 2015, 3, 80.	1.7	11
41	Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy. <i>American Journal of Roentgenology</i> , 2018, 211, 1342-1347.	2.2	10
42	Small molecules inhibitors of the heterogeneous ribonuclear protein A18 (hnRNP A18): a regulator of protein translation and an immune checkpoint. <i>Nucleic Acids Research</i> , 2021, 49, 1235-1246.	14.5	10
43	Restriction Spectrum Imaging Improves Risk Stratification in Patients with Glioblastoma. <i>American Journal of Neuroradiology</i> , 2017, 38, 882-889.	2.4	9
44	Isolated Loss of Hormonal Receptors in Leptomeningeal Metastasis From Estrogen Receptor $\alpha$ and Progesterone Receptor $\alpha$ -Positive Lobular Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, e200-e202.	1.6	8
45	Neoplastic meningitis resulting from hematological malignancies: pharmacokinetic considerations and maximizing outcome. <i>Clinical Investigation</i> , 2011, 1, 1391-1402.	0.0	7
46	Cellular target engagement: a new paradigm in drug discovery. <i>Future Medicinal Chemistry</i> , 2018, 10, 1641-1644.	2.3	7
47	Wnt pathway: a hallmark of drug discovery challenge. <i>Future Medicinal Chemistry</i> , 2018, 10, 1399-1403.	2.3	4
48	Cellular thermal shift analysis for interrogation of CRISPR-assisted proteomic changes. <i>BioTechniques</i> , 2020, 68, 180-184.	1.8	4
49	Phase I dose-escalation, safety, and CNS pharmacokinetic study of dexanabinol in patients with brain cancer. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab006.	0.7	4
50	Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.7	4
51	Overcoming tumor immune evasion with an unique arbovirus. <i>Journal of Translational Medicine</i> , 2015, 13, 3.	4.4	3
52	Breaking down the blood-brain barrier. <i>Neuro-Oncology</i> , 2021, 23, 6-6.	1.2	1
53	Successful and durable response of primary CNS T-cell lymphoma to upfront temozolomide monotherapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 2044-2046.	1.3	1
54	A community affair in the tumor microenvironment. <i>Oncotarget</i> , 2017, 8, 106173-106174.	1.8	1

#	ARTICLE	IF	CITATIONS
55	ATNT-19 TUMOR TREATING FIELDS WITH CHEMOTHERAPY COMPARED TO CHEMOTHERAPY ALONE IN GLIOBLASTOMA PATIENTS AT FIRST RECURRENCE: A POST-HOC ANALYSIS OF THE EF-14 TRIAL. Neuro-Oncology, 2015, 17, v14.4-v14.	1.2	0
56	DDEL-17 CSF PHARMACOKINETICS AND PHARMACODYNAMICS IN BRAIN CANCER PATIENTS ON HIGH-DOSE ERLOTINIB. Neuro-Oncology, 2015, 17, v77.1-v77.	1.2	0
57	ATPS-64 PRECLINICAL STUDIES USING NATIVIS VOYAGER RFE SYSTEM, A NOVEL NON-INVASIVE, LOW ENERGY, NON-THERMAL, NON-IONIZING RADIOFREQUENCY ENERGY (RFE) DEVICE IN GLIOBLASTOMA MOUSE MODELS. Neuro-Oncology, 2015, 17, v32.2-v32.	1.2	0